MALABSORPTON SYNDROME Prof Dr Tufan KUTLU Malabsorption n
MALABSORPTİON SYNDROME Prof. Dr. Tufan KUTLU
Malabsorption n Malabsorption can be defined as subnormal intestinal absorption of dietary constituents, and thus excessive loss of nutrients in the stool; it may be due to a digestive defect, a mucosal abnormality, or lymphatic obstruction. ”
Characteres of stools in childhood 0 -6 months Breast milk 1 -12/day yellow to braun p. H: 5 Formula 1 -7/day yellow to braun p. H: 7 6 months-1 year >1 year braun 2 -3/day as adult 5 -10 g/kg/day
Diarrhea u Increase in the number of stools or a decrease in their consistency n Constipation u Decrease in the number of stools or an increase in their consistency n
Malabsorption syndrome Chronic diarrhea n Protuberant abdomen n Vomiting n Weigth loss n Short stature n Anorexia. . n
Digestion of carbohydrates n n Carbohydrates n Enzymes u Starch 50 % u Salivary amylase u Sucrose 20 -40 % u Pancreatic amylase u Lactose 20 -40 % u Disaccharidase Monosaccharides u Glycose u Galactose u Fructose t Sucrase-isomaltase t Glucoamylase t Lactase
Carbohydrate malabsorption n Sucrase-izomaltase deficiency n Primary lactase deficiency n Late onset lactase deficiency n Glycose-galactose malabsorption n Secondary disaccharidase deficiency
Digestion of proteins n Gastric asid n Enterokinase n Pancreatic proteases
Protein malabsorption n Kongenital enterokinase deficiency n Pancreatic enzyme deficiency n Aminoacid transport defects
Digestion of lipids n Gastric lipase n Pancreatic n Bile lipase acids n Absorption
Steatorrhea n Pancreatic deficiency u u Congenital t Cystic fibrosis t Shwachman-Diamond syndrome t Johanson-Blizzard syndrome t Pearson’s syndrome Acquired t Chronic pancreatitis
Steatorrhea n Bile acid deficiency u Diminution of synthesis in the liver u Bile duct atresia u İncrease of bacterial deconjugation u u Diminution of ileal reabsorption (Crohn’s disease, ileal resection, short gut) Drugs (cholestyramine)
Steatorrhea n Abetalipoproteinemia u Retinitis pigmentosa u Neurologic symptoms u Achantocytosis u Cholesterol very low u Treatment: no fat, MCT, vitamine ADEK supplementation n Hypobetalipoproteinemia
Steatorrhea n n Intestinal lymphangiectasia u Hypoalbuminemia u Lymphopenia u Edema Mucosal absorption disorders u Celiac disease u Short gut
Gastrointestinal diseases associated with maldigestion and malabsorption Intraluminal digestion Stomach Pernicious anemia
Gastrointestinal diseases associated with maldigestion and malabsorption Intraluminal digestion Pankreas Cystic fibrosis Shwachman-Diamond syndrome Acute/chronic pancreatitis Tyripsinogen deficiency Lipase deficiency Amylase deficiency
Gastrointestinal diseases associated with maldigestion and malabsorption Intraluminal digestion Liver İntestine Cholestasis syndromes Enterokinase deficiency Short bowel syndrome
Gastrointestinal diseases associated with maldigestion and malabsorption Digestion at the enterocyte membrane Congenital disaccharidase deficiency Acquired/late-onset disaccharidase deficiency Lactase Sucrase-isomaltase Trehalase Lactase Sucrase-isomaltase Glucoamylase
Gastrointestinal diseases associated with maldigestion and malabsorption Enterocyte absorption Glucose-galactose malabsorption Congenital chloride diarrhea Abetalipoproteinemia Hypobetalipoproteinemia Celiac disease Short bowel syndrome Milk/soy protein intolerance Whipple’s disease Inflamatory bowel disease Infections Acrodermatitis enteropathica
Gastrointestinal diseases associated with maldigestion and malabsorption Uptake into blood and lymph Miscellaneus disorders Congestive heart failure Constrictive pericarditis Intestinal lymphangiectasia Intestinal lymphoma Carsinoid syndrome Immun deficiency syndromes Allergic gastroenteropathy Eosinophilic gastroenteropathy Drugs
Presenting symptoms Chronic diarrhea n Rectal bleeding n Meteorismus n Abdominal pain n Weigth loss n Failure to thrive n Constipation n Tenesmus n Vomiting n Anorexia n Pallor n Weakness n Fever n Geophagia n
Physical findings Weigth loss n Short stature n Protuberant abdomen n Ascites n Edema n Hepatomegaly n Splenomegaly n Clubbing n Pallor n Gingival hipertrophy n Aphthous mouth ulcers n Arthritis n Eritema nodosum n Uveitis, episcleritis n
Diagnostic studies in the evaluation of maldigestion and malabsorption I Stool examination for blood, leukocytes, reducing substances, C. difficile toxin, ova and parasites and cultures for infectious bacterial pathogens n Complete blood count, serum electrolytes, blood urea nitrogen, creatinine, calcium, phosphorus, albumin, total protein n Urinalysis and culture n
Diagnostic studies in the evaluation of maldigestion and malabsorption II Sweat chloride test n Breath analysis n D-Xylose test n Serum carotene, folate, B 12, and iron levels n Fecal alpha-1 -antitrypsin level n Fecal fat studies or coefficient of fat absorption studies n
Diagnostic studies in the evaluation of maldigestion and malabsorption III Fat-soluble vitamin levels: A, D, E, K n Contrast radiographic studies: upper gastrointestinal series, or barium enema n Gastroscopie/colonoscopie n Small intestinal biopsy for histology, and mucosal enzyme determination n
Antibodies Anti-gliadin ab n Anti-endomisium ab n Anti-transglutaminase ab n Autoantibody n p-ANCA, ASCA n
Sweat test indications Failure to thrive n Chronic diarrhea n Rectal prolapsus n Neonatal cholestasis n Cirrhosis n Pancreatitis n Recurrent pulmonary infections n Nasal polyps n Meconium ileus n Positive family history n
Disorders with sweat test positivity Cystic fibrosis n Adrenal insufficiency n Protein-calorie malnutrition n Neonatal cholestasis n G-6 -PD deficiency n Pancreatitis n Glycogen storage diseases n Hypoparathyroidism n Hypothyroidism n Nephrogenic diabetes insipidus n Ectodermal dysplasia n
Causes of villous atrophy in infants and children n n n Peptic duodenitis Celiac disease Acute gastroenteritis Cow’s milk and soy protein intolerance Eosinophilic gastroenteritis Immunodeficiency: congenital, acquired, AIDS Crohn’s disease Protein-calorie malnutrition Total parenteral nutrition Bacterial overgrowth or stasis Microvillus inclusion disease Autoimmune enteropathy Giardiasis
Relative value of a small-bowel biopsy n n n n Diagnostic biopsy Celiac disease Congenital microvillous atrophy Immunodeficiency Eosinophilic gastroenteritis Crohn’s disease Abetalipoproteinemia Chylomicron retention disease Lymphangiectasia (mucosal type) Diagnostic or non diagnostic Autoimmun enteropathy Crohn’s disease Tropical sprue Isolated Ig. A deficiency Lymphangiectasia Giardiasis n n n n Nonspesific changes Milk or soy protein intolerance Intractable diarrhea AIDS Malnutrition Drug and radiation-induced lesions Contaminated small-bowel syndrome Graft-versus-host disease
Specialized studies Schilling test n Serum/urine bile acid determination n Endoscopic retrograde pancreatography n Provocative pancreatic secretion testing n
Causes of chronic diarrhea in neonates n n n n n Cow’s or soy milk intolerance Glucose-galactose malabsorption Sucrase-isomaltase deficiency Congenital lactase deficiency Necrotizing enterocolitis Infections Cystic fibrosis Shwachman disease Abetalipoproteinemia Chylomicron retention disease n n n n Primary immunodeficiency Short bowel syndrome Intestinal lymphangiectasia Acrodermatitis enteropathica Microvillous inclusion disease Congenital chloride diarrhea Congenital bile salt malabsorption Congenital enterokinase deficiency
CELİAC DİSEASE
Celiac disease n Celiac disease (CD), also called glutensensitive enteropathy, is a permanent intestinal intolerance to dietary wheat gliadin and related proteins that produces mucosal lesions in genetically susceptible individuals
Historical background Gallen, 250 AD, described celiac disease n Samuel Gee, 1888, first description of CD n Dicke, 1950, role of wheat and rye flour in the pathogenesis of CD n Paulley, 1954, first biopsy (surgical) n Sakula ve Shiner, 1957, peroral intestinal biopsy n ESPGHAN criteria, 1970, 1979, 1990, 2012 n
Genetics of celiac disease Prevalence of CD among first-degree relatives of CD patients is approximately 10 % n 75 % of monozygotic twins have been found concordant with the disaese n Association of CD (95 % in CD, 20 -30 % in controls) with the HLA DQ α/β heterodimer encoded by the DQA 1*0501 and the DQB 1*0201 genes n
Epidemiology The reported prevalence of symptomatic CD is 1 in 1000 live births (1/250 – 1/4000) n The prevalence of asymptomatic CD is 1/200 (1/100 -1/300) n
Pathogenesis CD is an immunologically mediated small intestinal enteropathy. n The mucosal lesions shows features suggesting both humoral- and cell-mediated immunologic overstimulation. n All the evidence available suggests a glutendependent activation of mucosal immunity in CD. n
Pathology n n n Partial to total villous atrophy Elongated crypts Increased mitotic index in the crypts Increased intraepitelial lymphocytes Infiltrations of plasma cells and lymphocytes as well as mast cells, eosinophils, and basophils in the lamina propria
Clinical presentation Vomiting n Anorexia n Chronic diarrhea n Weigth loss n Irritability n Failure to thrive n Abdominal distention n Muscle wasting n
Clinical presentation Short stature n Delayed puberty n Anemia n Rickets-osteomalasia n Joint complaints n Cryptogenetic hepatitis n Epilepsy n
Cerrahpaşa experience; Age at the time of diagnosis Age (year) n % <2 >4 >10 24 48 12 28. 6 57. 1 14. 3
Symptoms Diarrhea: 85, 5 % n Abdominal distention: 41 % n Weigth loss: 27, 7 % n Failure to thrive: 20, 5 % n Vomiting: 19, 3 % n Anorexia: 18, 1 % n Abdominal pain: 13, 2 % n Constipation: 3, 6 % n
Physical findings Height < 3. p. : 60, 7 % n Weight < 3. p. : 66, 7 % n Hepatomegaly: 38, 1 % n Clubbing: 17, 9 % n Ascites: 8, 3 % n Edema: 4, 8 % n
Laboratory findings Anemia: 50 % n Trombocytosis: 64. 7 % n Low Fe: 60 % n Low ferritin: 78, 4 % n
Associated diseases n n n Dermatitis herpetiformis Down syndrome Autoimmune diseases u Thyroid diseases u Addison’s disease u Sarcoidosis u Insulin-dependent diabetes mellitus u Autoimmune hepatitis u Alopecia…
Down syndrome-celiac disease n The prevalence of celiac diseae in Down syndrome: 1 - 18 %
Insulin-dependent diabetes mellitusceliac disease n The prevalence of celiac diseae in insulindependent diabetes mellitus: 1, 5 - 8 %
Laboratory findings n n n Anemia Trombocytosis Folic acid deficiency B 12 deficiency Hypoproteinemia Hypertransaminasemia
Diagnosis n n n Antigliadin antibodies Anti-endomysium antibodies Anti tissue transglutaminase antibodies Small intestinal biopsy Response to gluten-free diet
Diagnosis n ESPGHAN criteria u Finding of villous atrophy with hyperplasia of the crypts and abnormal surface epithelium, while the patient eating adequate amounts of gluten. u A full clinical remission after witdrawal of gluten from the diet. u The finding of circulating antibodies to gliadin and endomysium at the time of diagnosis and their disappearence on a gluten-free diet, adds weight to the diagnosis.
Diagnosis n ESPGHAN criteria u A control biopsy to verify the consequences on the mucosal architecture of the gluten-free diet is considered mandatory only in patients with equivocal clinical response to the diet and in patients asymptomatic at first presentation.
Diagnosis n Gluten challenge is not considered mandatory, except under unusual circumstances. These include situations where there is doupt about the initial diagnosis, for exemple when no initial biopsy was done, or when the biopsy specimen was inadequate or not typical of CD. The diagnostic challenge may be necessary to exclude other causes that could be responsible for the flat mucosa.
Therapy n n Gluten-free diet; wheat, rye, barley and oats should be excluded Iron Folic acid Lactose-free diet
Therapy n Gluten-free diet
Gluten-free bread
Celiac disease-cancer n It has been demonstrated that the risk of developing small intestinal lymphoma is increased in patients taking a reduced-gluten or a normal diet, whereas for patients who have taken a strict gluten-free diet for 5 years or more the risk of developing malignancies over all sites is not increased when compared with the general population.
Celiac disease n All the present evidence strongly supports the view that restriction of gliadin should be complete and for life for all patients.
- Slides: 58